Novocure Ltd. Stock

$11.32

2.16% day before yesterday

Nasdaq, Aug 01, 10:00 pm CET

ISIN

JE00BYSS4X48

Symbol

NVCR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Overview Dividends Analysts Charts News Strategies

Novocure Ltd. Stock price

$11.32

-65.99 85.36% 5Y

Nasdaq, Closing price Fri, Aug 01 2025

-0.25 2.16%

ISIN

JE00BYSS4X48

Symbol

NVCR

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health Care Equipment & Services

Industry

Health Care Equipment & Supplies

Key metrics

Basic

Market capitalization

$1.3b

Enterprise Value

Net debt

Cash

Shares outstanding

Valuation (TTM | estimate)

P/E

negative | negative

P/S

2.0 | 2.0

EV/Sales

- | -

EV/FCF

P/B

Financial Health

Equity Ratio

29.0%

Return on Equity

-46.8%

ROCE

ROIC

Debt/Equity

Financials (TTM | estimate)

Revenue

$630.2m | $642.5m

EBITDA

$-156.9m | $-66.9m

EBIT

$-169.2m | $-188.6m

Net Income

$-171.0m | -

Free Cash Flow

$-80.4m

Growth (TTM | estimate)

Revenue

14.6% | 6.2%

EBITDA

8.7% | 57.5%

EBIT

7.6% | -12.0%

Net Income

-1.3% | -

Free Cash Flow

23.0%

EPS

$-1.5

FCF per Share

Short interest

7.0%

Employees

Rev per Employee

$410.0k

As a Free StocksGuide user, you can view scores for all 7,028 stocks worldwide.

Get Started for Free Today

Novocure Ltd. Stock Analysis

Unlock Scores for Free

??

13 Analysts have issued a Novocure Ltd. forecast:

10x Buy

77%

3x Hold

23%

More details on Analyst Estimates Including Price Targets

13 Analysts have issued a Novocure Ltd. forecast:

Buy

77%

Hold

23%

Analyst Estimates with Stock Price Targets

Financial data from Novocure Ltd.

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '25		+/- %
Revenue	630 630	15% 15% 100%
- Direct Costs	148 148	11% 11% 23%
Gross Profit	483 483	16% 16% 77%
- Selling and Administrative Expenses	439 439	14% 14% 70%
- Research and Development Expense	213 213	1% 1% 34%
EBITDA	-157 -157	9% 9% -25%
- Depreciation and Amortization	12 12	10% 10% 2%
EBIT (Operating Income) EBIT	-169 -169	8% 8% -27%
Net Profit	-171 -171	1% 1% -27%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Novocure Ltd. Stock News

Positive

Seeking Alpha

●

4 days ago

NovoCure's Wearable Oncology Edge And Compelling Valuation

NVCR focuses on Tumor Treating Fields wearables for GBM, mesothelioma, and NSCLC. These are its main recurring revenue verticals. So far, its wearables have shown favorable safety profiles, and suggest they should be a net benefit across other oncology niches. NVCR's late‑stage PANOVA‑3 and METIS trials could continue growing their markets. Currently, management is targeting more PMA filings la...

Neutral

Seeking Alpha

●

8 days ago

NovoCure Limited (NVCR) Q2 2025 Earnings Call Transcript

NovoCure Limited (NASDAQ:NVCR ) Q2 2025 Earnings Conference Call July 25, 2025 8:00 AM ET Company Participants Ashley Cordova - CEO & Director Christoph Brackmann - Chief Financial Officer Frank Leonard - Executive VP & President of Novocure Oncology Ingrid Goldberg - VP of Investor Relations William F. Doyle - Executive Chairman Conference Call Participants Emily Claudia Bodnar - H.C.

Neutral

The Motley Fool

●

9 days ago

NovoCure Q2 Revenue Jumps 6 Percent

NovoCure (NVCR -23.93%), the oncology device firm advancing Tumor Treating Fields therapy, released its second quarter 2025 results on July 24, 2025. GAAP revenue totaled $158.8 million in Q2 2025, an increase of 6% year over year and surpassing the $154.16 million analyst consensus (GAAP).

More Novocure Ltd. News

Company Profile

NovoCure Ltd. develops treatment for tumors. Its platform is called the Tumor Treating Field which used electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

Head office	Jersey
CEO	Ms. Cordova
Employees	1,488
Founded	2000
Website	www.novocure.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now